Tag Archive for: Pluvicto

If its label expansion is approved, earlier Pluvicto treatment may help patients avoid the toxic side effects of chemotherapy — and may open a larger market for the targeted treatment.

The company has ramped up its sales growth target as a result of demand for innovative drugs after the spin off of its generics business.

Pluvicto improved radiographic progression-free survival in PSMA-positive patients with metastatic castration-resistant prostate cancer who had not been treated with taxane-based chemotherapy.

To sharpen its focus on its core therapeutic areas, Novartis is discontinuing or licensing out 10% of its clinical development programs, the company announced Tuesday during its first-quarter financial report call with investors.

Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) – the company’s second win in this indication in as many months.

With Novartis facing a potential loss of $9 billion through 2026 from patent expirations, the company announced topline results for Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world’s largest pharmaceutical market.